BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
BioVie was invited to give a late-breaking oral presentation on bezisterim in Long COVID at the 4th Long COVID International Conference in Nice, France on November 13, including previously unshared biomarker data. The Phase 2 ADDRESS-LC trial (~200 patients, fully funded by a $13.13 million U.S. Department of War grant) showed a consistent trend toward improvement versus placebo, with statistically significant gains confined to pre-specified high-symptom-burden subgroups representing roughly 78% of participants.
Key figures
- Drug Name
- bezisterim (NE3107)
- Phase Of Trial
- Phase 2
- Dosing
- 20 mg oral capsule twice daily
- Trial name
- ADDRESS-LC
- Trial funding
- $13.13 million U.S. Department of War PRMRP award
- Trial enrollment
- 203
- Symptom burden coverage
- 78% of trial participants affected in at least one domain
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.